Market Context — Why This Technology, Why Now

The increasing complexity of biologics and gene therapies demands advanced solutions for protein manufacturing. Current methods often struggle with aggregation and inefficient folding, leading to significant yield losses and quality control challenges. This technology directly addresses these issues, enabling manufacturers to meet stringent regulatory standards and accelerate time-to-market for novel therapeutics amidst intense global competition and rising R&D costs.

Key Competitive Advantages
01

Accelerates protein folding, potentially reducing process time by ~20% compared to conventional agents.

02

Effectively inhibits protein aggregation, potentially improving product loss rates by an average of 5%.

03

Achieves equivalent or superior effects with ~1/3 the additive amount compared to conventional technologies.

Market Opportunity
Biopharmaceutical Manufacturing
$6.5B+ globally (AI est.)
The increasing demand for complex protein formulations drives the market, as highly efficient folding and aggregation inhibition directly improve manufacturing yield and quality stability.
Large-scale biopharmaceutical manufacturers Contract Development and Manufacturing Organizations (CDMOs) Specialty protein drug producers
Drug Discovery and Development
$2B–$2.5B globally (AI est.)
Efficiently obtaining stable, active proteins is crucial for accelerating research and increasing success rates in novel drug candidate screening and protein function analysis.
Pharmaceutical R&D departments Biotech startups in drug discovery Academic research institutions
Advanced Functional Materials Development
$1B–$1.5B globally (AI est.)
This technology is expected to be a foundational technology for stably supplying high-quality proteins for materials development utilizing protein functions, such as enzymes, biosensors, and regenerative medicine materials.
Medical device manufacturers Diagnostic kit developers Enzyme and biomaterial producers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the specific structure of a cyclic diselenide compound, along with its use as a protein folding agent and the associated protein folding method, across four claims. Its novelty and inventiveness were clearly recognized despite prior art, establishing a stable and robust intellectual property foundation for licensees.

Competitive White Space

This patent protects the compound and its use in protein folding. Licensees could build IP around specific delivery systems or integration with advanced protein purification technologies.

Economic Impact
~$150K/year estimated production cost savings per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

In biopharmaceutical manufacturing, reducing protein aggregation loss by an average of 5% across 500 annual production batches could save ~$125K/year (AI est.) (based on ~$250/batch loss). Additionally, using ~1/3 the reagent amount compared to conventional methods could save ~$30K/year in reagent costs (AI est.). This totals over ~$150K/year in estimated production cost savings per facility (AI est.).

Speed to Market
6× faster than in-house development
This technology's cyclic diselenide compound structure and synthesis methods are well-established, with its mechanism of action thoroughly validated through fundamental university research. With molecular design and basic evaluations already complete, licensees can significantly reduce R&D time. As the technology is available for licensing, it provides a solid foundation for early integration into existing protein manufacturing processes or use as a reagent.
Competitive Positioning

X: Production Efficiency Improvement
Y: Quality Stability

Business Models & Applications
🧪 Protein Folding Reagent Sales
Develop and sell protein folding reagents, with this cyclic diselenide compound as the main component, directly to pharmaceutical companies and research institutions.
🏭 Licensing for Biopharmaceutical Manufacturing Processes
Offer licenses to biopharmaceutical manufacturers for integrating this technology into their production processes. This model generates revenue through licensing fees and royalties by improving production efficiency and reducing costs.
🤝 Collaborative Research & Contract Development
Provide technical expertise through collaborative research or contract development for optimizing folding conditions for specific proteins or for new biopharmaceutical development projects, earning research and development fees or success-based payments.
Adjacent Application Opportunities
🔬 Drug Screening
High-Efficiency Drug Candidate Evaluation System
This technology could enable the creation of systems for rapidly and accurately assessing how new drug candidates affect target protein folding. This is expected to enhance screening efficiency in early drug discovery, contributing to shorter development times and reduced costs.
🧪 Biosensor Development
High-Sensitivity, High-Stability Biosensor Elements
By improving the stability of proteins used as detection elements in biosensors, this technology could significantly boost sensor sensitivity and lifespan. This is anticipated to enable the development of more reliable biosensors for medical diagnostics, environmental monitoring, and food testing.
🧬 Gene Therapy Drug Manufacturing
Enhanced Quality for Viral Vector Production
Applying this technology to the manufacturing of gene therapy viral vectors, such as adeno-associated virus (AAV), could inhibit vector aggregation and improve both quality and yield. This has the potential to contribute to the stable supply and optimized manufacturing costs of gene therapy drugs.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: Technology Evaluation & PoC
Duration: 3 months
Conduct folding tests with the licensee's specific proteins to evaluate the technology's efficacy, optimal additive amount, and aggregation inhibition effects. Verify compatibility with existing processes and establish a baseline for implementation benefits.
Phase 2: Process Optimization & Pilot Scale Validation
Duration: 9 months
Based on PoC results, optimize folding conditions for the licensee's manufacturing process. Validate reproducibility, stability, and scalability through pilot-scale testing.
Phase 3: Full-Scale Production Line Integration
Duration: 6 months
Develop an integration plan for full-scale production lines based on pilot validation insights, applying the technology incrementally. Aim to maximize manufacturing efficiency and product quality through continuous evaluation and improvement from initial deployment to full operation.
Technical Feasibility
This technology's cyclic diselenide compound can be easily integrated as an additive into existing protein purification and manufacturing processes. Its specific compound structure is clearly defined, and synthesis methods are established, allowing for implementation without new equipment or major line modifications. Leveraging existing reactors and purification systems means low technical hurdles and rapid deployment.
Success Scenario
Implementing this technology could resolve protein folding bottlenecks in biopharmaceutical manufacturing, potentially reducing manufacturing lead times by ~20%. This could enable a 1.2x increase in annual production while enhancing product quality stability, strengthening market competitiveness. Furthermore, reducing product loss due to aggregation could lead to hundreds of thousands of dollars in annual cost savings (AI est.).
Patent Record
APPLICATION NO.
特願2020-201618
REGISTRATION NO.
7606207
FILING DATE
2020/12/04
GRANT DATE
2024/12/17
EXPIRATION DATE
2040/12/04
PATENT HOLDER
学校法人東海大学
Examination History
2023年11月07日
出願審査請求書
2024年12月03日
特許査定